Table 3.
Patient characteristics by mutation status (randomised population)11
| BRAFV600E (n=598) | BRAFV600K (n=57) | |
|---|---|---|
| Median age (years) | 53·0 (44·0–62·0) | 63·0 (47·0–65·0) |
|
| ||
| Geographical region | ||
| Australia/New Zealand | 72 (12%) | 5 (9%) |
| North America | 144 (24%) | 23 (40%) |
| Other | 18 (3%) | ·· |
| Western Europe | 364 (61%) | 29 (51%) |
|
| ||
| ECOG PS | ||
| 0 | 407 (68%) | 43 (75%) |
| 1 | 191 (32%) | 14 (25%) |
|
| ||
| Metastatic classification | ||
| M1a | 66 (11%) | 6 (11%) |
| M1b | 118 (20%) | 8 (14%) |
| M1c | 389 (65%) | 39 (68%) |
| Unresectable stage IIIc | 25 (4%) | 4 (7%) |
| Serum LDH elevated | 254 (42%) | 21 (37%) |
Data are number of patients (%), unless otherwise indicated. ECOG PS=Eastern Cooperative Oncology Group performance status. LDH=lactate dehydrogenase. Reprinted with permission from Massachusetts Medical Society, who own the copyright.